A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer.
Ricardo FernandesTerry L NgMashari Jemaan AlzahraniJacques RaphaelPhillip BlanchetteMorgan BlackCarol StoberGregory R PondDavid CellaLisa VandermeerMohammed IbrahimMark J Clemonsnull nullPublished in: Current oncology (Toronto, Ont.) (2023)
A randomized trial comparing P-H and TC-H was feasible. Expansion to a larger trial would be feasible to explore patient-reported outcomes of these adjuvant HER2 chemotherapy regimens.